Somatostatin
Somatostatin is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 38916-34-6[1] |
| PubChem CID | 16129706[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C76H104N18O19S2[1] |
| Molecular weight | 1637.9 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Somatostatin is a cyclic peptide hormone that inhibits growth hormone release, which is why it is researched alongside the secretagogue and GHRH-analogue classes indexed here. A 1983 New England Journal of Medicine review carries the name as its title, a 1999 Frontiers in Neuroendocrinology review covers the peptide and its receptor family, a 2000 Science paper reports hetero-oligomers of dopamine and somatostatin receptors, and a 1982 Life Sciences paper describes SMS 201-995, the octapeptide analogue later named octreotide.
The most-cited records are molecular biology of the gene: a 1986 Proceedings of the National Academy of Sciences paper identifies a cyclic AMP-responsive element in the rat somatostatin gene, a 1987 Nature paper reports binding of a nuclear protein to it, and a 1989 Cell paper reports that cyclic AMP stimulates transcription through phosphorylation of CREB at serine 133. Neuroanatomical records include a 1980 Neuroscience paper on the distribution of peptide-containing neurons in the gastrointestinal tract, a 1980 Nature paper on reduced somatostatin-like immunoreactivity in cerebral cortex in Alzheimer disease, and a 2003 Journal of Comparative Neurology paper on colocalisation in GAD67-GFP mice. A 2000 European Journal of Nuclear Medicine paper reports receptor subtype affinity profiles of somatostatin radiotracers.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
The endogenous ligand of the five somatostatin receptor subtypes, per the retrieved receptor-family review, acting as an inhibitory hormone on growth hormone and gut secretion.
[4, 3]Stated in the titles of the cited 1999 Frontiers in Neuroendocrinology and 1983 New England Journal of Medicine papers.
Targets named in the cited records: somatostatin receptors SST1 to SST5.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Somatostatin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- somatotropin release-inhibiting factor
- SRIF
- SST-14
Where this page sits
Research records
Cited research records for Somatostatin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Octreotide — Endocrine and immune signalling peptides
- Sermorelin — GHRH analogues
- Teriparatide — Endocrine and immune signalling peptides
- Vasoactive intestinal peptide — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Somatostatin?
Somatostatin is a cyclic peptide hormone that inhibits growth hormone release, which is why it is researched alongside the secretagogue and GHRH-analogue classes indexed here. A 1983 New England Journal of Medicine review carries the name as its title, a 1999 Frontiers in Neuroendocrinology review covers the peptide and its receptor family, a 2000 Science paper reports hetero-oligomers of dopamine and somatostatin receptors, and a 1982 Life Sciences paper describes SMS 201-995, the octapeptide analogue later named octreotide.
Which class is Somatostatin indexed under?
Somatostatin is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Somatostatin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 16129706, Somatostatin. PubChem, National Library of Medicine (2026). pubchem:16129706
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:somatostatin
- Somatostatin. The New England journal of medicine (1983). pmid:6139753
- Somatostatin and its receptor family. Frontiers in neuroendocrinology (1999). pmid:10433861
- Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science (New York, N.Y.) (2000). pmid:10753124
- SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life sciences (1982). pmid:6128648
- Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proceedings of the National Academy of Sciences of the United States of America (1986). pmid:2875459
- Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature (1987). pmid:2885756
- Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell (1989). pmid:2573431
- Distribution of peptide- and catecholamine-containing neurons in the gastro-intestinal tract of rat and guinea-pig: immunohistochemical studies with antisera to substance P, vasoactive intestinal polypeptide, enkephalins, somatostatin, gastrin/cholecystokinin, neurotensin and dopamine beta-hydroxylase. Neuroscience (1980). pmid:6156425
- Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature (1980). pmid:6107862
- Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. The Journal of comparative neurology (2003). pmid:14574680
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. European journal of nuclear medicine (2000). pmid:10774879
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.